Jefferies Financial Group Inc. Sells 369,178 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Jefferies Financial Group Inc. trimmed its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 97.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,158 shares of the medical device company's stock after selling 369,178 shares during the period. Jefferies Financial Group Inc.'s holdings in Tandem Diabetes Care were worth $330,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its position in shares of Tandem Diabetes Care by 163.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after acquiring an additional 1,101 shares during the last quarter. US Bancorp DE boosted its position in shares of Tandem Diabetes Care by 15.2% during the fourth quarter. US Bancorp DE now owns 38,708 shares of the medical device company's stock worth $1,394,000 after buying an additional 5,108 shares during the period. KBC Group NV increased its stake in Tandem Diabetes Care by 41.5% during the fourth quarter. KBC Group NV now owns 192,479 shares of the medical device company's stock worth $6,933,000 after purchasing an additional 56,461 shares during the period. Envestnet Portfolio Solutions Inc. lifted its holdings in Tandem Diabetes Care by 22.0% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 6,560 shares of the medical device company's stock worth $236,000 after buying an additional 1,184 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Tandem Diabetes Care by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock valued at $267,989,000 after purchasing an additional 77,451 shares during the period.

Insider Transactions at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos acquired 10,538 shares of the company's stock in a transaction dated Friday, March 7th. The shares were bought at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the purchase, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.90% of the stock is currently owned by corporate insiders.

Tandem Diabetes Care Stock Down 2.2%

TNDM stock traded down $0.45 during midday trading on Wednesday, reaching $20.18. The company had a trading volume of 1,327,514 shares, compared to its average volume of 1,496,916. The company has a market capitalization of $1.34 billion, a P/E ratio of -10.46 and a beta of 1.47. The company has a 50 day moving average of $19.48 and a two-hundred day moving average of $26.95. Tandem Diabetes Care, Inc. has a 1 year low of $15.75 and a 1 year high of $53.64. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The company had revenue of $234.42 million during the quarter, compared to analyst estimates of $220.19 million. During the same quarter in the previous year, the business posted ($0.65) EPS. The company's revenue was up 22.3% on a year-over-year basis. On average, equities research analysts expect that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TNDM has been the topic of a number of research analyst reports. The Goldman Sachs Group cut their price objective on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Citigroup boosted their target price on Tandem Diabetes Care from $20.00 to $24.00 and gave the stock a "neutral" rating in a research report on Thursday, May 22nd. Barclays dropped their price target on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Royal Bank of Canada decreased their price objective on Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. Finally, Stifel Nicolaus dropped their target price on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Eight equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $35.86.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.